The sixth company to come out ophthalmology incubator ForSight Labs said today that it raised $3.0 million from a syndicate of nine unnamed investors. Stealthy ForSight Vision6 revealed the equity round in a regulatory filing today. The company added $3.0 million in December 2014 to the $1 million is raised in 20153 from a lone backer. […]
Allergan (NYSE: AGN) said today it inked a deal to buy drug-eluting ophthalmological implant maker ForSight Vision5 for $95 million up front, with a possible milestone payment for launching its drug-eluting device. Pharmaceutical giant Allergan said the device, known as the Helios ring, is designed for extended drug delivery and for reducing intraocular pressure in […]
The Helios drug-eluting implant developed by ForSight Vision5 lowered intraocular pressure in glaucoma patients by about 20% after 6 months, according to study results published today in Ophthalmology, the journal of the American Academy of Ophthalmology. The Helios device is a thin, silicone ring impregnated with the glaucoma drug bimatoprost that’s designed to slowly release the drug […]
ForSight Vision5, which is developing devices to treat front-of-the-eye conditions such as glaucoma and dry eye disease, said today that it raised another $7.8 million. ForSight Vision5 is a spinout of ForSight Labs, a Menlo Park, Calif.-based incubator focused on developing ophthalmic treatments. Last year the company reeled in a $15 million Series C round. […]
California ophthalmic incubator ForSight Labs is seeking $6 million in order to fund its VISION6 project, the latest in a string of developments spun out of the company.
ForSight Vision5, which is developing devices to treat front-of-the-eye conditions such as glaucoma and dry eye disease, said it pulled down a $15 million Series C round.
ForSight Vision5 is a spinout of ForSight Labs, a Menlo Park, Calif.-based incubator focused on developing ophthalmic treatments.
ForSight Vision5, an early-stage ophthalmology company based in Silicon Valley, named venture capitalist and medtech veteran John Maroney as its new chief executive.